Tenofovir Alafenamide Fumarate Patent Expiration
Tenofovir Alafenamide Fumarate is Used for treating chronic hepatitis B in adult and pediatric patients. It was first introduced by Gilead Sciences Inc
Tenofovir Alafenamide Fumarate Patents
Given below is the list of patents protecting Tenofovir Alafenamide Fumarate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Vemlidy | US7390791 | Prodrugs of phosphonate nucleotide analogues | Apr 17, 2025 | Gilead Sciences Inc |
| Vemlidy |
US7390791 (Pediatric) | Prodrugs of phosphonate nucleotide analogues | Oct 17, 2025 | Gilead Sciences Inc |
| Vemlidy | US7803788 | Prodrugs of phosphonate nucoleotide analogues |
Feb 02, 2022
(Expired) | Gilead Sciences Inc |
| Vemlidy | US8754065 | Tenofovir alafenamide hemifumarate | Aug 15, 2032 | Gilead Sciences Inc |
| Vemlidy |
US8754065 (Pediatric) | Tenofovir alafenamide hemifumarate | Feb 15, 2033 | Gilead Sciences Inc |
| Vemlidy | US9296769 | Tenofovir alafenamide hemifumarate | Aug 15, 2032 | Gilead Sciences Inc |
| Vemlidy |
US9296769 (Pediatric) | Tenofovir alafenamide hemifumarate | Feb 15, 2033 | Gilead Sciences Inc |
Coming Soon
Patent Strength Analyzer
YesNo
Thank you for your response 🥳
Tenofovir Alafenamide Fumarate Generics
Several generic applications have been filed for Tenofovir Alafenamide Fumarate. The first generic version for Tenofovir Alafenamide Fumarate was by Lupin Ltd and was approved on Mar 30, 2023. And the latest generic version is by Apotex Inc and was approved on Mar 21, 2024.
Given below is the list of companies who have filed for Tenofovir Alafenamide Fumarate generic.
1. LUPIN LTD
Lupin Ltd has filed for 1 generic for Tenofovir Alafenamide Fumarate. This eq 25mg base version comes by the name TENOFOVIR ALAFENAMIDE. Given below are the details of the strengths of this generic introduced by Lupin Ltd.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 25MG BASE | tablet | Prescription | ORAL | AB | Mar 30, 2023 |
2. APOTEX
Apotex Inc has filed for 1 generic for Tenofovir Alafenamide Fumarate. Given below are the details of the strengths of this generic introduced by Apotex.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 25MG BASE | tablet | Discontinued | ORAL | N/A | Mar 21, 2024 |